Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vasily Belozeroff

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Journal of Medical Economics|February 9, 2012
Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United StatesRob Boer, Anjana M Lalla, Vasily Belozeroff
BMC Research Notes|July 10, 2019
Comparison of health state utility estimates from instrument-based and vignette-based methods: a case study in kidney diseaseAndrew H Briggs, Vasily Belozeroff, David Feeny
Journal of Medical Economics|August 15, 2017
Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapyBjörn Stollenwerk, Sergio Iannazzo, Kerry Cooper, et al.
BMC Health Services Research|July 4, 2013
Healthcare use and costs before and after parathyroidectomy in patients on dialysisVasily Belozeroff, Kerry Cooper, Gregory Hess, et al.
Sleep|March 12, 2003
Model-based assessment of autonomic control in obstructive sleep apnea syndromeVasily Belozeroff, Richard B Berry, Michael C K Khoo
Clinical Journal of the American Society of Nephrology : CJASN|March 6, 2009
Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patientsVasily Belozeroff, William G Goodman, Lulu Ren, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 4, 2008
Consistent control of mineral and bone disorder in incident hemodialysis patientsMark D Danese, Vasily Belozeroff, Karen Smirnakis, et al.
Journal of Medical Economics|July 23, 2013
Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcetVasily Belozeroff, Andrew Lee, Spring Tseng, et al.
BMC Nephrology|October 31, 2012
Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort studySilvia Chiroli, Caroline Mattin, Vasily Belozeroff, et al.
BMC Nephrology|July 29, 2017
Hemodialysis patients' preferences for the management of secondary hyperparathyroidismBrett Hauber, John Caloyeras, Joshua Posner, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Journal of Medical Economics|February 9, 2012
Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United StatesRob Boer, Anjana M Lalla, Vasily Belozeroff
BMC Research Notes|July 10, 2019
Comparison of health state utility estimates from instrument-based and vignette-based methods: a case study in kidney diseaseAndrew H Briggs, Vasily Belozeroff, David Feeny
Journal of Medical Economics|August 15, 2017
Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapyBjörn Stollenwerk, Sergio Iannazzo, Kerry Cooper, et al.
BMC Health Services Research|July 4, 2013
Healthcare use and costs before and after parathyroidectomy in patients on dialysisVasily Belozeroff, Kerry Cooper, Gregory Hess, et al.
Sleep|March 12, 2003
Model-based assessment of autonomic control in obstructive sleep apnea syndromeVasily Belozeroff, Richard B Berry, Michael C K Khoo
Clinical Journal of the American Society of Nephrology : CJASN|March 6, 2009
Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patientsVasily Belozeroff, William G Goodman, Lulu Ren, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 4, 2008
Consistent control of mineral and bone disorder in incident hemodialysis patientsMark D Danese, Vasily Belozeroff, Karen Smirnakis, et al.
Journal of Medical Economics|July 23, 2013
Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcetVasily Belozeroff, Andrew Lee, Spring Tseng, et al.
BMC Nephrology|October 31, 2012
Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort studySilvia Chiroli, Caroline Mattin, Vasily Belozeroff, et al.
BMC Nephrology|July 29, 2017
Hemodialysis patients' preferences for the management of secondary hyperparathyroidismBrett Hauber, John Caloyeras, Joshua Posner, et al.
Pageof 4